FBIOX Performance — Select Biotechnology Portfolio
Data updated: 2026-07-24
FBIOX returned +6.15% year to date and +55.70% over one year to May 2026. Annualised returns are +18.93% over 3 years and +6.71% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $168, against $131 for the category, and to $156 over one year, against $129. Volatility over the past three years was 19.07% a year. In the 12 months to May 2026 the fund lost a net $59.5M, and assets reached $5.27B.
FBIOX Growth of $100
What $100 invested in Select Biotechnology Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | FBIOX | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $156 | $129 |
| 3 years (Jun 2023 – May 2026) | $168 | $131 |
| 5 years (Jun 2021 – May 2026) | $138 | $116 |
| Since data start (Sep 2019 – May 2026) | $210 | $173 |
FBIOX Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +6.15% |
| 1 year | +55.70% |
| 3 years (annualised) | +18.93% |
| 5 years (annualised) | +6.71% |
FBIOX Annual Returns
Calendar-year total returns of Select Biotechnology Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +6.15% |
| 2025 | +36.39% |
| 2024 | +7.28% |
| 2023 | +10.07% |
| 2022 | −15.86% |
| 2021 | −12.43% |
| 2020 | +38.33% |
| 2019 (Sep–Dec) | +20.29% |
FBIOX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.5% | +2.4% | −1.8% | +0.4% | +3.6% | — | — | — | — | — | — | — |
| 2025 | +3.1% | +0.7% | −5.0% | −0.9% | −4.9% | +3.4% | +7.6% | +5.1% | +8.7% | +7.4% | +8.2% | −0.8% |
| 2024 | +1.5% | +7.9% | +0.9% | −10.5% | +4.7% | +5.3% | +8.3% | +1.5% | −0.3% | −0.1% | −1.5% | −8.8% |
| 2023 | +3.2% | −5.0% | −2.1% | +4.4% | +1.4% | +0.3% | +2.2% | −3.3% | −4.9% | −6.6% | +5.2% | +16.9% |
| 2022 | −16.1% | −2.8% | +2.5% | −13.7% | −3.9% | +8.1% | +4.3% | +4.7% | −2.1% | +3.5% | +3.1% | −1.5% |
| 2021 | +0.6% | +0.6% | −5.6% | +0.4% | −5.1% | +6.4% | −2.0% | +5.9% | −5.1% | −1.3% | −6.0% | −1.0% |
| 2020 | −4.4% | −0.4% | −10.4% | +15.6% | +11.2% | +4.0% | −3.6% | +3.0% | +1.7% | −0.5% | +14.9% | +5.3% |
| 2019 | — | — | — | — | — | — | — | — | −5.0% | +7.4% | +13.7% | +3.6% |
FBIOX Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 19.07%
- 3-year Sharpe ratio: 0.76 (vs 4.5% risk-free rate)
- Best month: +16.90% (Dec 2023)
- Worst month: −10.55% (Apr 2024)
FBIOX Fund Flows
Monthly money in and out of Select Biotechnology Portfolio, from SEC Form N-PORT.
- 12-month net flow: −$59.5M
- 12-month gross sales (incl. reinvestments): $829.4M
- Sales ÷ redemptions: 0.93×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $17.0M | $83.2M | −$66.2M |
| Apr 2026 | $233.1M | $76.2M | $156.9M |
| Mar 2026 | $15.4M | $83.6M | −$68.3M |
| Feb 2026 | $23.8M | $63.2M | −$39.3M |
| Jan 2026 | $55.1M | $92.7M | −$37.6M |
| Dec 2025 | $190.4M | $74.4M | $116.0M |
| Nov 2025 | $78.9M | $55.9M | $23.0M |
| Oct 2025 | $44.6M | $76.9M | −$32.3M |
| Sep 2025 | $19.6M | $73.5M | −$53.9M |
| Aug 2025 | $46.4M | $68.5M | −$22.1M |
| Jul 2025 | $96.3M | $81.6M | $14.7M |
| Jun 2025 | $8.9M | $59.3M | −$50.4M |
FBIOX Assets Under Management
Net assets of Select Biotechnology Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $5.27B |
| 2026-02-28 | $5.35B |
| 2025-11-30 | $5.27B |
| 2025-08-31 | $4.23B |
| 2025-05-31 | $3.67B |
| 2025-02-28 | $4.28B |
| 2024-11-30 | $4.75B |
| 2024-08-31 | $5.01B |
| 2024-05-31 | $4.47B |
| 2024-02-29 | $4.92B |
| 2023-11-30 | $4.02B |
| 2023-08-31 | $4.59B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.